AMENDMENTS TO THE SPECIFICATION:

Amend the specification as follows:

Page 1, after the title, insert the following new paragraph:

The present application is a 371 U.S. national phase of PCT/FR99/02752, filed 9 November 1999, which designated the U.S., and claims benefit of U.S. Provisional application Serial No. 60/122,600, filed 3 March 1999.

Page 29, delete the paragraph on line 12 and insert the following therefor:

~~**FIGURE LEGENDS**~~ BRIEF DESCRIPTION OF THE DRAWINGS

Page 31, delete the paragraph spanning lines 12-14 and insert the following therefor:

Figure 6: Nucleotide sequence of the tTA gene ~~(A)~~; the the UMS sequence ~~(B)~~; of the Op sequence ~~(C)~~ and of the minimal CMV promoter ~~(D)~~.(SEQ ID NO:1)

Delete the paragraph spanning page 34, line 25 through page 35, line 12 and insert the following therefor:

The human cells were detected by hybridization using a human-specific alu primer which was labeled with digoxigenin-tagged nucleotides (5'-XTTgCAgTgAgCCgAgATCgCgCC-3'(SEQ ID NO:2)). After an initial denaturation step (20 minutes in 95% formamide, 0.1 × SSC at 75° and with shaking), sections were treated as previously

described (Dumas et al., J. Chem. Neuroanat. 5 (1992) 11). Human TH-1 RNA was detected in the implants by in situ hybridization using a 35 sulfur-labeled oligonucleotide which was directed against exon 1 of human TH (5'-TgCCTgCTTggCgTCCAgCTCAgACA-3' (SEQ ID NO:3)). The hybridization conditions are identical to those described by Lanièce et al. (J. Neurochem. 66 (1996) 1819). For the immunohistochemistry, the sections were treated in accordance with standard techniques.

Insert the attached Sequence Listing in place of the copy of the Sequence Listing filed September 28, 2001.